Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 6/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3752235 | 0.96 | ALDH1A1 (0.46) | ALDH1A1TSHRTHRBTDP1RECQL | |
| SCHEMBL3749937 | 0.93 | ALDH1A1 (0.48) | ALDH1A1TSHRTHRBTDP1KDM4E | |
| SCHEMBL3748063 | 0.89 | ALDH1A1 (0.52) | ALDH1A1TSHRTHRBTDP1 | |
| SCHEMBL30513275 | 0.87 | TSHR (0.53) | TSHRMEN1KMT2A | |
| SCHEMBL14798778 | 0.86 | PHF8 (0.43) | ALDH1A1TSHRTHRBKDM4E | |
| SCHEMBL27826454 | 0.86 | ALDH1A1 (0.41) | ALDH1A1TSHRTHRBTDP1 | |
| SCHEMBL6153042 | 0.84 | ALDH1A1 (0.48) | ALDH1A1TSHRTHRBTDP1 | |
| SCHEMBL28718766 | 0.78 | ALDH1A1 (0.41) | ALDH1A1TSHRTHRBTDP1MAPT | |
| SCHEMBL22852547 | 0.78 | ALDH1A1 (0.41) | ALDH1A1TSHRTHRBTDP1 | |
| SCHEMBL16376102 | 0.77 | ALDH1A1 (0.55) | ALDH1A1TSHRTHRBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838699-B2 | Embolization using degradable crosslinked hydrogels | BIOSPHERE MEDICAL (US) | 2010-11-23 | — | — | US | disclosed |
| US-7135593-B2 | Degradable crosslinkers, and degradable crosslinked hydrogels comprising them | BIOSPHERE MEDICAL, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| US-20050113285-A1 | Degradable crosslinkers, and degradable crosslinked hydrogels comprising them | WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2005-05-26 | — | — | US | disclosed |
| US-6713646-B2 | Degradable crosslinkers, and degradable crosslinked hydrogels comprising them | BIOSPHERE MEDICAL | 2004-03-30 | — | — | US | disclosed |
| US-20030215519-A1 | Embolization using degradable crosslinked hydrogels | WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2003-11-20 | — | — | US | disclosed |
| WO-2003086316-A2 | DEGRADABLE CROSSLINKERS, AND DEGRADABLE CROSSLINKED HYDROGELS COMPRISING THEM | BIOSPHERE MEDICAL, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030199654-A1 | DEGRADABLE CROSSLINKERS, AND DEGRADABLE CROSSLINKED HYDROGELS COMPRISING THEM | WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113285-A1 | Degradable crosslinkers, and degradable crosslinked hydrogels comprising them | GFER, RAD52, ESD | ALDH1A1 497/4885TSHR 2627/4885THRB 4649/4885 |
| US-20030199654-A1 | DEGRADABLE CROSSLINKERS, AND DEGRADABLE CROSSLINKED HYDROGELS COMPRISING THEM | GFER, RAD52, ESD | ALDH1A1 497/4885TSHR 2627/4885THRB 4649/4885 |
| US-20030215519-A1 | Embolization using degradable crosslinked hydrogels | PLG, PLAU, FGB | ALDH1A1 1040/4885TSHR 1876/4885THRB 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.